OncLive TV

Pedro Barata, MD, MSc, discusses remaining unmet needs for patients with prostate cancer.

Varun Monga, MD, discusses the investigation of the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in patients with recurrent high-grade glioma or uveal melanoma.

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

Pau Montesinos, MD, PhD, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia.

Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.

Nicholas Coupe, MBBS, PhD, discusses the investigation of IMM60 plus pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer.

Francisco Javier Esteva, MD, PhD, discusses key findings from the phase 3 NATALEE trial in patients with hormone receptor–positive, HER2-negative early breast cancer.

Martin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Eileen M. O'Reilly, MD, discusses survival outcomes from the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Nikhil C. Munshi, MD, discusses potential future directions for ciltacabtagene autoleucel and other CAR T-cell therapies in patients with multiple myeloma.

Erika P. Hamilton, MD, discusses the investigation of patritumab deruxtecan in heavily pretreated patients with metastatic estrogen receptor-positive or triple-negative breast cancer with varying levels of HER3 expression in a phase 2 trial.

Amira Marouf, MD, PhD student, discusses the efficacy of PD-L1 inhibitors in relapsed/refractory extranodal natural killer/T-cell lymphoma.

John Mascarenhas, MD, discusses initial clinical activity observed with the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in primary or secondary myelofibrosis.

Benjamin Miron, MD, discusses the rationale for investigating molecular alterations in patients with intraductal carcinoma of the prostate.

Kanwal P. S. Raghav, MBBS, MD, discusses the rationale behind the phase 2 DESTINY-CRC02 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with metastatic colorectal cancer (mCRC) with HER2 amplification or overexpression.

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Helena A. Yu, MD, discusses findings from a phase 1 trial investigating the bispecific antibody-drug conjugate BL-B01D1, which is directed against both HER3 and EGFR, in patients with locally advanced or metastatic solid tumors such as non–small cell lung cancer and small cell lung cancer.

Barbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.

Susan Bal, MD, discusses the toxicity profile of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, according to findings from a phase 1 trial.

Susan Bal, MD, discusses updated safety and efficacy data from the dose-escalation and dose-expansion portions of phase 1 trial of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in patients with relapsed/refractory multiple myeloma.

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.

Shubham Pant, MD, MBBS, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors.

Nausheen Ahmed, MD, discusses findings from a real-world subgroup analysis of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.

Pasi A. Jänne, MD, PhD, discusses findings from a first-in-human phase 1 trial investigating the EGFRxHER3 bispecific antibody-drug conjugate BL-B01D1 in patients with advanced non–small cell lung cancer and other advanced solid tumors.

Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.

Matthew Frank, MD, PhD, discusses preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

Amin Nassar, MD, discusses findings from a retrospective study of the use of EGFR TKI therapy, durvalumab, or observation following concurrent chemoradiation in patients with unresectable, stage III non–small cell lung cancer harboring EGFR mutations.

Nabil F. Saba, MD, FACP, discusses key findings from the phase 3 CONTINUUM trial of sintilimab plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Julien Taieb, MD, PhD, discusses key findings from a post-hoc analysis of the phase 3 SUNLIGHT trial of combination of trifluridine/tipiracil with bevacizumab in patients with refractory metastatic colorectal cancer.

Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.